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Hepcidin, the systemic regulator of iron homeostasis is activated by proteins responsible for hereditary
hemochromatosis, bonemorphogenetic proteins (BMPs), and inflammatory cytokines. Three recent publica-
tions now identify a novel hepcidin suppressor, the transmembrane serine protease TMPRSS6 (also known
as matriptase-2), which is required to sense iron deficiency.Balancing systemic iron levels within
narrow limits is critical for human health:
diseases of iron deficiency and overload
belong to the most frequent disorders
worldwide. Regulation of systemic iron
homeostasis evolved tomaintain aplasma
iron concentration that secures adequate
supplies while preventing organ iron over-
load. The regulatory system responds to
signals from pathways that consume
iron (e.g., erythropoiesis) and transmits
signals to cells that supply iron (e.g., duo-
denal enterocytes that absorb dietary
iron, macrophages that recycle iron from
effete erythrocytes, and hepatocytes that
store iron). The small hepatic peptide
hormone hepcidin synchronizes these
systemic iron fluxes by binding to the
iron export channel ferroportin located
on the surface of macrophages, hepato-
cytes, and intestinal enterocytes to cause
its internalization and proteolysis. In ac-
cordancewith this mechanism chronically
elevated hepcidin levels (e.g., in the ane-
mia of chronic diseases; ACD) cause sys-
temic iron deficiency and inappropriately
low hepcidin levels (e.g., in hereditary
hemochromatosis; HH) result in iron over-
load (Nemeth and Ganz, 2006). Here, we
review recent advances that identify the
transmembrane serine proteaseTMPRSS6
as a suppressor of hepcidin expression.
TMPRSS6 is mutated in individuals with
iron-refractory iron deficiency anemia
(IRIDA) and is critical for adequate dietary
iron uptake to prevent iron deficiency
(Du et al., 2008; Folgueras et al., 2008;
Finberg et al., 2008).
Key research within the field aims to
identify activators and suppressors of
hepcidin synthesis. Hepcidin activators
include proteins responsible for heredi-tary hemochromatosis (HFE, TfR2, and
hemojuvelin [HFE2]) and the bone mor-
phogenetic proteins (BMPs) that induce
hepcidin transcription via the SMAD sig-
naling pathway (e.g., Babitt et al., 2006;
Wang et al., 2005) (Figure 1). Additionally,
inflammatory cytokines increase hepcidin
expression via the JAK/STAT pathway
(Wrighting and Andrews, 2006). Compar-
atively little is known about mechanisms
that suppress hepcidin synthesis during
iron deficiency. In recent work by Du
et al. (2008), such a negative regulator of
hepcidin expression, the putative serine
protease TMPRSS6, was discovered. A
role for TMPRSS6 in maintaining iron ho-
meostasis was identified when the chem-
ically induced mutant mouse phenotype
‘‘mask’’ was analyzed that is character-
ized by progressive loss of body hair, mi-
crocytic anemia, low plasma iron levels,
and low body iron stores. Themaskmuta-
tion maps to chromosome 15 and gener-
ates abnormal splice products that lack
the proteolytic domain of TMPRSS6.
TMPRSS6 mutant mice show impaired
dietary iron uptake and fail to suppress
hepcidin mRNA expression in response
to dietary iron deficiency. More recently,
analysis of a mouse line with a TMPRSS6
null allele yielded highly similar data and
extended the observations from mask
mutant mice in that high hepatic hepcidin
mRNA levels correlate with low ferroportin
protein expression and iron accumulation
in duodenal enterocytes (Folgueras et al.,
2008). TMPRSS6 thus is required to ren-
der mice sensitive to low iron stores and
to suppress hepcidin expression. Consis-
tent with the data in mice, TMPRSS6
overexpression in a hepatoma cell line de-
creases hepcidin promoter activity andCell Mecounteracts stimuli known to activate
hepcidin expression. How TMPRSS6 reg-
ulates the expression of hepcidin is still
unknown but the crosstalk to the hepcidin
promoter involves the proximal 200 bp
adjacent to the start of transcription (Du
et al., 2008) where the STAT-3 binding
site that controls IL6-mediated hepcidin
transcription (Verga Falzacappa et al.,
2006) and the multifunctional BMP-re-
sponsive element important for both
HJV/BMP and IL6-mediated hepcidin ac-
tivation (Verga Falzacappa et al., 2008)
are located.
In an independent study, Finberg
et al. (2008) investigated gene defects in
five families characterized by congenital
hypochromic, microcytic anemia, low
mean corpuscular erythrocyte volume,
and low transferrin saturation. Because
in these individuals anemia does not re-
solve following treatment with oral iron
and the response to parenteral iron ad-
ministration is incomplete, this disease
entity is termed iron-refractory iron defi-
ciency anemia (IRIDA). Genetic analysis
of these families indicates linkage of
IRIDA to chromosome 22q12-13. Inter-
estingly, the TMPRSS6 gene is located
within this critical interval, and mutations
in the TMPRSS6 gene are detected in all
five families studied in addition to two in-
dividuals with sporadic IRIDA. All identi-
fied mutations lie distal to exon 8 in the
highly conserved region of the conserved
trypsin-like serine protease domain that
was shown by Du et al. (2008) to be re-
quired for TMPRSS6-mediated hepcidin
suppression in cultured cells. Consistent
with the findings in mask mutant (Du
et al., 2008) and TMPRSS6 knockout (Fol-
gueras et al., 2008) mice, urinary hepcidintabolism 8, July 2008 ª2008 Elsevier Inc. 1
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propriately high, although hepcidin is typ-
ically undetectable in patients with iron
deficiency. Chronically elevated hepcidin
expression prevents iron release from du-
odenal enterocytes andmacrophages ex-
plaining why both orally applied and par-
enteral injected iron cannot be efficiently
utilized by IRIDA patients. While in many
aspects the phenotype of IRIDA patients
resembles the one of TMPRSS6-deficient
mice (Table 1), it is currently unclear why
oral and parenteral iron application is
unable to normalize iron deficiency in
individuals with IRIDA while anemia and
hair loss is resolved upon iron treatment
in both murine TMPRSS6-deficiency
models (Du et al., 2008; Folgueras et al.,
2008). Analysis of hepcidin expression in
TMPRSS6-deficient mice following iron
application may yield further insight into
this question.
Three recent studies suggest that
TMPRSS6 suppresses hepcidin produc-2 Cell Metabolism 8, July 2008 ª2008 Elsevietion to permit adequate dietary iron up-
take. If active hepcidin suppression fails
due to TMPRSS6 inactivation, severe
iron deficiency prevails. TMPRSS6 is pre-
dominantly expressed in the liver and
consists of a C-terminal, extracellular
trypsin-like serine protease domain, three
low density lipoprotein receptor (LDLR)
tandem repeats, two CUB (complement
factor C1s/C1r, urchin embryonic growth
factor, bone morphogenetic protein) do-
mains, and a membrane-proximal SEA
(sea urchin sperm protein, enteropepti-
dase, agrin) domain that contains a poten-
tial cleavage motif that may release the
enzyme from the cell surface. TMPRSS6
cleaves extracellular matrix proteins
in vitro (Velasco et al., 2002), but it is not
understood whether this function is re-
quired to maintain iron homeostasis or
whether additional phenotypes exist in
TMPRSS6-deficient mice. Future studies
also need to address how TMPRSS6-me-
diated hepcidin suppression is fine tunedr Inc.to maintain systemic iron levels within
narrow limits. Possibilities include binding
of a putative ligand to the TMPRSS6 ex-
tracellular domain whose expression is
regulated by systemic iron availability. Al-
ternatively, TMPRSS6 expression levels
may be controlled directly by intracellular
iron levels. Further, it will be interesting to
unravel how TMPRSS6 suppresses hep-
cidin transcription. In principal, TMPRSS6
protease cleavage and/or TMPRSS6-me-
diated signalingmay function to inactivate
a protein involved in a hepcidin activating
pathway as those controlled by IL6, the
HH-associated proteins, and BMPs (Fig-
ure 1). Alternatively, TMPRSS6 may acti-
vate a protein involved in a hepcidin
suppressing pathway. Hypoxia inducible
factor (HIF)-1a, growth differentiation
factor (GDF) 15, and a cleavage product
of hemojuvelin that is detectable in the
plasma were previously implicated as
hepcidin suppressors. The finding that
TMPRSS6 regulates hepcidin transcriptionFigure 1. Regulation of Hepcidin Transcription by TMPRSS6
Hepcidin transcription is activated in response to interleukin 6 (IL6) via the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway and
a STAT3-responsive element (STAT3-RE) at position69/72 of the hepcidin promoter or a receptor complex that requires the activities of the HH proteins HFE,
TfR2, and HFE2 (a BMP coreceptor), the BMP receptor, as well as the ligands BMP2 or 4. Binding of HFE to transferrin receptor (TfR) 1 and TfR2 was demon-
strated. A common model suggests that iron-bound transferrin and BMPs control signal transduction from this receptor complex to regulate hepcidin transcrip-
tion via the SMAD signaling pathway. BMP-responsive elements are located at positions 79/84 and between 1600/1800 of the hepcidin promoter. The
liver-expressed hepcidin suppressor TMPRSS6 inhibits hepcidin activation in response to IL6, HFE2, and BMP. This may be achieved by extracellular protease
cleavage of a component that is common to these signaling pathways. Alternatively and/or additionally, TMPRSS6 signaling may interfere with HH protein-me-
diated hepcidin activation via the SMAD pathway or an as-yet-unidentified independent signaling pathway that overrides activating stimuli utilizing promoter
elements within the proximal promoter region. Whether or not a ligand is involved in fine tuning TMPRSS6 activity is subject to further investigation. Gray lines
with arrows indicate hepcidin-activating pathways. Red lines indicate putative locations at which TMPRSS6 may inhibit hepcidin activation.
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tains two activating elements (Wrighting
and Andrews, 2006; Verga Falzacappa
et al., 2006, 2008) may give first clues
regarding such a mechanism.
The identification of TMPRSS6 as
a novel hepcidin regulator is an important
advancement in our understanding of
hepcidin regulation that may have clinical
implications for the treatment of frequent
iron disorders: inhibition of the putative
protease functionmay be applied in disor-
ders such as HH or iron-loading anemias,
in which hepcidin levels are inappropri-
ately low. Similarly, strategies stimulatingTMPRSS6 may be useful in ACD that is
hallmarkedbyhighhepcidin levels. The re-
quirement for both activating and repres-
sing pathways to maintain precise hep-
cidin levels underscores the importance
for tight control of hepcidin expression.
Mutations in HFE, TfR2, hemojuvelin, and
hepcidin explain most known cases of he-
reditary hemochromatosis. Therefore, the
discovery of novel hepcidin regulators in
the future is likely to arise from the sub-
group of hepcidin suppressors that con-
trol the response to iron deficiency and
maybemutated in so-far-uncharacterized
cases of anemias in patients and mice.Cell MeACKNOWLEDGMENTS
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37637–37646.Table 1. Clinical and Biochemical Parameters in IRIDA Patients Mask Mice and Mice
with a TMPRSS6 Null Allele
IRIDA Patients
(Finberg et al., 2008)
Mask Mutant
Mice (Du et al., 2008)
TMPRSS6/ Mice
(Folgueras et al., 2008)
Red blood
cell counts (RBC)
Normal range ND ND
Hemoglobin (Hb) Low Low Low
Mean corpuscular
volume (MCV)
Low Low Low
Plasma iron levels ND Low Low
Transferrin saturation Low ND Low
Iron absorption Abnormal Abnormal Abnormal
Hepcidin levels High High High
Iron stores
(spleenic iron)
ND Low ND
Abnormal iron absorption in IRIDIA patients was concluded by a lack of hematological improve-
ment following treatment with oral iron. In mask mutant mice, iron absorption was reduced, while
in TMPRSS6/ mice low ferroportin expression and iron accumulation within duodenal entero-
cytes was indicative of anomalies in dietary iron uptake. Low in IRIDA patients indicates that values
lie below the respective reference range. "Low" or "High" in TMPRSS6-deficient mice indicates
that values are significantly lower or higher, respectively, compared to wild-type mice. ND, not
determined.tabolism 8, July 2008 ª2008 Elsevier Inc. 3
